Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148756 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03148756 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 2 participants.
The verdict
NCT03148756, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.
Interventions
- DRUG Standard of Care
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-05-12 |
| Est. Completion | 2017-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03148756
The ClinicalTrials.gov registry entry for NCT03148756 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03148756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03148756 about?
NCT03148756 is a clinical study titled "Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis". This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.
What is the current status of trial NCT03148756?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-05-12. Estimated completion is 2017-08-04.
What interventions are being tested in trial NCT03148756?
The interventions under investigation include: Standard of Care (DRUG), Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT03148756?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.